Astellas to Acquire Iveric Bio for $5.9B, Expanding Eye Disease Pipeline
Astellas Pharma agreed to acquire Iveric Bio for approximately $5.9 billion, in a deal designed to expand the buyer’s eye treatment pipeline.
Source: genengnews.com
Stay updated with breaking news from Astella Blindness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Astellas Pharma agreed to acquire Iveric Bio for approximately $5.9 billion, in a deal designed to expand the buyer’s eye treatment pipeline.